CalciMedica (CALC) details 2025 executive pay, ownership and $20.4M raise
CalciMedica (CALC) has filed an amendment to its annual report (10-K/A), detailing 2025 executive compensation, board governance, ownership stakes, and related-party transactions, as well as a $20.4 million private placement from 2024. The filing specifies executive pay, significant equity awards, and severance policies, with CEO A. Rachel Leheny receiving $895,410 in total compensation for 2025. It also updates information on major shareholders and outlines fees paid to the independent auditor.
How this was made
The 30-second read
Why it matters
The disclosures improve transparency, which could bolster investor confidence, but lack immediate catalysts for stock movement.
Market read
The news is relevant for investors interested in CALC's fundamentals and governance, with limited immediate trading impact.
What to watch
Potential upcoming regulatory changes or market conditions affecting biotech funding and valuations that are not addressed in this news.
Background
CalciMedica is a biotech company with recent activities including a significant private placement and detailed governance disclosures, indicating ongoing development and funding.
Ticker impact
The news pertains directly to CalciMedica's financial disclosures, executive compensation, ownership, and recent funding activities, which are highly relevant for current and potential investors.
Limited immediate impact; potential for long-term growth if funding translates into operational success.
While the financial details are comprehensive, they do not signal immediate market-moving events. The neutral sentiment and lack of significant positive or negative cues suggest limited short-term price volatility.
The news provides detailed insights into CALC's financial and governance activities, which are relevant for investors monitoring company fundamentals.
Potential for minor positive movement over the medium term as transparency improves investor perception.
The news enhances transparency but lacks immediate catalysts for significant price changes. The impact depends on how investors interpret the company's governance and funding activities.
Market effects
The updates on corporate governance and funding may positively influence investor confidence in biotech and life sciences sectors.
Limited regional impact; specific to CALC and its immediate investor base.
Minimal; company-specific news with limited global market implications.
Counterpoint
Some investors may interpret the detailed disclosures as a sign of underlying issues or strategic shifts that could negatively impact stock performance.
Key entities
- ExecutiveA. Rachel Leheny
CEO of CalciMedica, received $895,410 in total compensation for 2025.
- CompanyCalciMedica
Biotech firm with recent financial disclosures and funding activities.





